Navigation Links
Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans
Date:5/18/2009

Free Medication Provided by Shire to Patients Taking Lialda(R) (mesalamine) or Pentasa(R) (mesalamine) for the Treatment of Ulcerative Colitis Who Have Lost Their Jobs in 2009

PHILADELPHIA, May 18 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, is responding to the needs of patients who are diagnosed with ulcerative colitis (UC) and prescribed gastrointestinal (GI) medications from Shire by expanding its Patient Assistant Program (PAP). Thanks to the recently enhanced Shire CARES PAP, UC patients who are newly prescribed or are already taking Lialda or Pentasa and who become unemployed in 2009 can receive their medication at no cost throughout the rest of the calendar year. In addition, more UC patients can benefit from Lialda and Pentasa because Shire has raised the household income levels necessary to qualify for no cost and shared cost assistance. This expands the existing Shire PAP to help even more uninsured patients and their families save on the medicines they need to stay healthy and to manage chronic conditions like UC.

"We are committed to helping UC patients better manage their condition," said Roger Adsett, senior vice president of the GI business unit at Shire. "Offering greater financial support to those who may be struggling due to the current economic climate through our expanded Shire CARES PAP is a natural extension of the Shire mission."

More than 100,000 people with UC have been treated with Lialda, and many have benefited from the Shire PAP. The new Shire CARES PAP includes job loss prescription coverage for 2009, and financial assistance at no cost and shared cost levels. Additionally, the Shire CARES PAP offers a discounted copay pharmacy card program (not valid in Mass.) and a 30-day free trial of Lialda when patients join the Lialda UC Support Program. The Lialda UC Support program offers patients the added benefit of hearing from professionals for medical insight and advice through an unbranded patient education Web site.

"We are thrilled to launch this new, more robust program," said Mike Cola, president of the Specialty Pharmaceuticals business at Shire. "The program is designed to help patients with ulcerative colitis who are taking Lialda or Pentasa and are experiencing a financial hardship gain access to these treatments. This enhanced PAP is the first of many steps Shire is taking to reinforce our commitment to the patient community, and we are pleased that Lialda and Pentasa are leading the way."

The Shire CARES PAP has a simple enrollment process and offers free delivery of medicines for enrolled patients to their home or doctor's office for up to one year. Patients may be re-enrolled if they continue to need assistance and qualify for the Shire CARES PAP.

To learn more about the Shire CARES PAP for Lialda and Pentasa medications, please call 1-888-CARES-55 to speak with a live representative, or visit www.lialda.com.

    For Further information please contact:
    Media                      Sarah McGee (GolinHarris)      +1 312 729 4125
                               Matthew Cabrey (Shire)         +1 484 595 8248

About Lialda

Important Safety Information

Lialda is approved for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of Lialda beyond 8 weeks have not been established. You should not take Lialda if you are allergic to salicylates (including mesalamine or aspirin) or to any of the ingredients of Lialda. Tell your doctor if you have a stomach blockage or are allergic to sulfasalazine. Mesalamine has been associated with a syndrome that may be difficult to distinguish from an ulcerative colitis flare-up. If you experience cramping, diarrhea, fever, headache or rash, talk to your doctor immediately. Some patients taking mesalamine have reported heart-related hypersensitivity reactions, such as inflammation of the heart muscle and inflammation of the lining of the heart. Tell your doctor if you have problems with your liver or kidneys.

In worldwide clinical trials, Lialda was generally well tolerated. The most common adverse events were headache and flatulence. As with other medications, some serious side effects may occur. Less than 1% of patients experienced inflammation of the pancreas, which led to discontinuation of therapy with Lialda.

Lialda(R) is a registered trademark of Shire LLC.

MMX(R) is a registered trademark owned by Cosmo Technologies Ltd, Ireland, a wholly-owned subsidiary of Cosmo Pharmaceuticals SpA.

About PENTASA

Important Safety Information

PENTASA is approved for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis.

PENTASA is generally well tolerated and most side effects are mild. In worldwide clinical studies, the most common side effects were diarrhea, headache, nausea, abdominal pain, upset stomach, vomiting, and rash. As with other medications, some serious side effects may occur. You should not take PENTASA if you are allergic to salicylates, such as aspirin. Tell your doctor if you have problems with your liver or kidneys. While taking PENTASA, visit your doctor periodically. If you have any questions about PENTASA, please talk to your doctor.

Pentasa(R) is a registered trademark of Ferring A/S Corp.

About SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's Web site: www.shire.com

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18
2. Growth in New Hampshire Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
3. IntelliSoft Group Contracts with New England Hospitals: Berkshire Health Systems and Porter Medical Center
4. New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure
5. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
6. Shire Celebrates World Rare Disease Day on February 28
7. Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions
8. Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions
9. Anthem Blue Cross and Blue Shield in New Hampshire Ranks Among Top Insurers on U.S. News & World Report / National Committee for Quality Assurance Best Health Plans List
10. Anthem Blue Cross and Blue Shield in New Hampshire Associates Pledge More Than $260,000 to Community Organizations
11. New Hampshire Seniors Speak Out Against Medicare Advantage Cuts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix ... of Emergency Medicine , an emergency medicine professional association, to support the organization's ... , The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 Executive Forum, ... 200 of the country’s top healthcare executives to share insights on transformational strategies ... the Forum is the provider-centric perspective, experience, expertise and strategy shared by the ...
(Date:2/10/2016)... ... 2016 , ... Armune BioScience signed a definitive agreement with ... centers across the country. Launched in April of 2015, Apifiny is the only cancer ... Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... it will attend the Ohio Safety Congress and Expo event March 9-11, 2016. ... the Greater Columbus Convention Center. , As the longest running and largest ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Visage Imaging Inc. ... Ltd. (ASX: PME), has announced that the American College ... (UF) have selected the Visage 7 Enterprise Imaging ... the Emergent/Critical Care Imaging SIMulation (SIM). SIM is ... Imaging Program (WIDI), a multi-faceted and fully-integrated online ...
(Date:2/10/2016)... DIEGO , Feb. 10, 2016 ... company developing novel, clinical-stage therapies for sickle cell disease ... underwritten public offering of 29,090,910 units at a price ... consists of one share of the Company,s common stock ... Company,s common stock at an exercise price of $0.42 ...
(Date:2/10/2016)... Antibacterial Drugs Market - Global Industry ... ", reveals that the global antibacterial drugs market is forecast ... owing to patent expiries of blockbuster drugs. Even though the ... forecast period, the value is anticipated to decline from US$43.9 ... Antibacterial Drugs Market - Global Industry Analysis, Size, Share, ...
Breaking Medicine Technology: